Sydnexis Welcomes Erin Horn as Vice President, Head of Market Access

January 19,2023 – Sydnexis, Inc. (www.sydnexis.com), a clinical stage biopharmaceutical company focused on the treatment of progressive myopia in children and minimizing the risk of associated co-morbidities, is excited to announce the appointment of Erin Horn as its Vice President, Head of Market Access.  With a strong and diverse track record of commercial success in traditional and specialty ophthalmic pharmaceuticals, Erin will provide her market access, launch expertise, and commercial leadership to Sydnexis’ ongoing expansion and growth.

Erin will lead Sydnexis’ market access, pricing, contracting, and go-to-market strategies.  With 25 years of industry experience, Erin brings a wealth of knowledge in leading ophthalmic product launches and building successful brands and teams.

“We are thrilled that Erin has joined Sydnexis in pursuit of our mission. Erin brings a wealth of knowledge, expertise, and direct experience with market access customers and organizations that is unsurpassed in Ophthalmology. She is adynamic addition to the Sydnexis leadership team and we are extremely excited for her future success,” said Nick Ruth, Chief Commercial Officer at Sydnexis.

Read the rest of the press release here on Sydnexis’ site or a PDF copy of the story by clicking here.